A detailed history of Pier Capital, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Pier Capital, LLC holds 165,486 shares of DNLI stock, worth $4.67 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares
165,486
Previous 172,331 3.97%
Holding current value
$4.67 Million
Previous $3.54 Million 8.65%
% of portfolio
0.6%
Previous 0.5%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$14.96 - $23.22 $102,401 - $158,940
-6,845 Reduced 3.97%
165,486 $3.84 Million
Q1 2024

May 02, 2024

SELL
$15.83 - $23.35 $29,887 - $44,084
-1,888 Reduced 1.08%
172,331 $3.54 Million
Q4 2023

Feb 15, 2024

BUY
$16.2 - $23.18 $796,051 - $1.14 Million
49,139 Added 39.29%
174,219 $3.74 Million
Q3 2023

Nov 14, 2023

SELL
$20.63 - $30.17 $42,250 - $61,788
-2,048 Reduced 1.61%
125,080 $2.58 Million
Q2 2023

Aug 14, 2023

BUY
$23.37 - $32.96 $2.97 Million - $4.19 Million
127,128 New
127,128 $3.75 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.79B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Pier Capital, LLC Portfolio

Follow Pier Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pier Capital, LLC with notifications on news.